{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:20:35Z","timestamp":1791559235391,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"crossref","award":["2011.085.1\u20132"],"award-info":[{"award-number":["2011.085.1\u20132"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsf\u00f6rderung","award":["ELAN VI-15-04-07-1"],"award-info":[{"award-number":["ELAN VI-15-04-07-1"]}]},{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.antiviral.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T00:41:12Z","timestamp":1470789672000},"page":"130-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors"],"prefix":"10.1016","volume":"134","author":[{"given":"C.","family":"Hutterer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Steingruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Zeittr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bahsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Thuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"\u00d6rfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"\u00d6rfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Socher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sticht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Rawlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.J.","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.08.005_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.semperi.2007.01.002","article-title":"Recent advances in the prevention and treatment of congenital cytomegalovirus infections","volume":"31","author":"Adler","year":"2007","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib2","doi-asserted-by":"crossref","first-page":"334e339","DOI":"10.1016\/j.jviromet.2011.03.005","article-title":"A\u00a0reporter system for Epstein-Barr virus (EBV) lytic replication: anti-EBV activity of the broad anti-herpesviral drug artesunate","volume":"173","author":"Auerochs","year":"2011","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.antiviral.2016.08.005_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1099\/vir.0.022293-0","article-title":"Modification of the major tegument protein pp 65 of human cytomegalovirus inhibits virus growth and leads to the enhancement of a protein complex with pUL69 and pUL97 in infected cells","volume":"91","author":"Becke","year":"2010","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib4","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.08.005_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00126839-200607020-00002","article-title":"Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer","volume":"7","author":"Buschbeck","year":"2006","journal-title":"Drugs R. D."},{"key":"10.1016\/j.antiviral.2016.08.005_bib6","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.08.005_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/rmv.574","article-title":"Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir","volume":"18","author":"Chou","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib8","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.00186-10","article-title":"Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.08.005_bib9","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.00511-13","article-title":"Cytomegalovirus UL97 kinase catalytic domain mutations that confer multi-drug resistance","volume":"57","author":"Chou","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.08.005_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in\u00a0vitro and in\u00a0vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.08.005_bib11","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.49.7.2710-2715.2005","article-title":"Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene","volume":"49","author":"Chou","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.08.005_bib12","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/AAC.00207-06","article-title":"Effect of cell culture conditions on the anticytomegalovirus activity of maribavir","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.08.005_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1086\/518514","article-title":"Cytomegalovirus UL97 kinase mutations that confer maribavir resistance","volume":"196","author":"Chou","year":"2007","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.08.005_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.antiviral.2016.08.005_bib15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","article-title":"Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia","volume":"29","author":"Cortes","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/clpt.2010.178","article-title":"Update on new antivirals under development for the treatment of double-stranded DNA virus infections","volume":"88","author":"Dropulic","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2016.08.005_bib17","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1128\/JVI.73.5.4110-4119.1999","article-title":"Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection","volume":"73","author":"Elliott","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib18","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jsgi.2005.02.008","article-title":"Establishment and characterization of a human first-trimester extravillous trophoblast cell line (TEV-1)","volume":"12","author":"Feng","year":"2005","journal-title":"J.\u00a0Soc. Gynecol. Investig."},{"key":"10.1016\/j.antiviral.2016.08.005_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.bcp.2010.03.033","article-title":"Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines","volume":"80","author":"Galetti","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib20","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","author":"Goldner","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1386-6532(00)00155-4","article-title":"Cytomegalovirus diagnosis in renal and bone marrow transplant recipients: the impact of molecular assays","volume":"20","author":"Halwachs-Baumann","year":"2001","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1071\/MA15057","article-title":"Therapeutics to prevent congenital cytomegalovirus during pregnancy: what is available now and in the future?","volume":"36","author":"Hamilton","year":"2015","journal-title":"Microbiol. Aust."},{"key":"10.1016\/j.antiviral.2016.08.005_bib23","doi-asserted-by":"crossref","first-page":"e97231","DOI":"10.1371\/journal.pone.0097231","article-title":"Human cytomegalovirus replication is strictly inhibited by siRNAs targeting UL54, UL97 or UL122\/123 gene transcripts","volume":"9","author":"Hamilton","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2016.08.005_bib56","doi-asserted-by":"crossref","first-page":"e1000275","DOI":"10.1371\/journal.ppat.1000275","article-title":"Viral mimicry of Cdc2\/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress","volume":"5","author":"Hamirally","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2016.08.005_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrc1506","article-title":"Gefitinib - a novel targeted approach to treating cancer","volume":"4","author":"Herbst","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.antiviral.2016.08.005_bib25","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1128\/AAC.48.11.4154-4162.2004","article-title":"Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity","volume":"48","author":"Herget","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.08.005_bib26","series-title":"New Concepts of Antiviral Therapy","first-page":"351","article-title":"Recent developments in anti-herpesviral combination therapy based on protein kinase inhibitors","author":"Herget","year":"2006"},{"key":"10.1016\/j.antiviral.2016.08.005_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2015.10.003","article-title":"The broad-spectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-\u03baB) pathway by targeting RelA\/p65","volume":"124","author":"Hutterer","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.08.005_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.antiviral.2013.04.017","article-title":"Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK","volume":"99","author":"Hutterer","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.08.005_bib29","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2010-09-310862","article-title":"Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias","volume":"117","author":"Karp","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2016.08.005_bib30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.antiviral.2016.08.005_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.placenta.2005.03.003","article-title":"Human cytomegalovirus-induced inhibition of cytotrophoblast invasion in a first trimester extravillous cytotrophoblast cell line","volume":"27","author":"LaMarca","year":"2006","journal-title":"Placenta"},{"key":"10.1016\/j.antiviral.2016.08.005_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.08.005_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.coph.2008.07.002","article-title":"Antiviral strategies to combat cytomegalovirus infections in transplant recipients","volume":"8","author":"Lischka","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-385987-7.00004-X","article-title":"Regulatory roles of protein kinases in cytomegalovirus replication","volume":"80","author":"Marschall","year":"2011","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.antiviral.2016.08.005_bib35","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.44.6.1588-1597.2000","article-title":"Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents","volume":"44","author":"Marschall","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.08.005_bib36","doi-asserted-by":"crossref","first-page":"33357","DOI":"10.1074\/jbc.M502672200","article-title":"Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina","volume":"280","author":"Marschall","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.08.005_bib37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2217\/fmb.09.40","article-title":"Molecular targets for antiviral therapy of cytomegalovirus infections","volume":"4","author":"Marschall","year":"2009","journal-title":"Future Microbiol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib38","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1099\/0022-1317-82-6-1439","article-title":"Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97","volume":"82","author":"Marschall","year":"2001","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1099\/0022-1317-83-5-1013","article-title":"Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy","volume":"83","author":"Marschall","year":"2002","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.08.005_bib41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jviromet.2006.07.019","article-title":"Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients","volume":"138","author":"Mazet-Wagner","year":"2006","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.antiviral.2016.08.005_bib42","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2141.2010.08427.x","article-title":"Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications","volume":"152","author":"McMillin","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1087057104270269","article-title":"Identification of inhibitors for a virally encoded protein kinase by two different screening systems: in-vitro kinase assay and in-cell activity assay","volume":"10","author":"Mett","year":"2005","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.antiviral.2016.08.005_bib44","doi-asserted-by":"crossref","first-page":"13979","DOI":"10.1074\/jbc.M109.063628","article-title":"Novel mode of phosphorylation-triggered reorganization of the nuclear lamina during nuclear egress of human cytomegalovirus","volume":"285","author":"Milbradt","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.08.005_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.placenta.2014.11.003","article-title":"Ex\u00a0vivo model of congenital cytomegalovirus infection and new combination therapies","volume":"36","author":"Mor\u00e8re","year":"2015","journal-title":"Placenta"},{"key":"10.1016\/j.antiviral.2016.08.005_bib46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib47","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1021\/jm060696s","article-title":"Analysis of the structure-activity relationship of four herpesviral UL97 subfamily protein kinases reveals partial but not full functional conservation","volume":"49","author":"Romaker","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2016.08.005_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2008.01.154","article-title":"Protein kinase inhibitors of the quinazoline class exert anticytomegaloviral activity in\u00a0vitro and in\u00a0vivo","volume":"79","author":"Schleiss","year":"2008","journal-title":"Antivir. Res."},{"issue":"Suppl.\u00a0A","key":"10.1016\/j.antiviral.2016.08.005_bib49","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1053\/plac.2001.0647","article-title":"Cell culture models of human trophoblast II: trophoblast cell lines-a workshop report","volume":"22","author":"Shiverick","year":"2001","journal-title":"Placenta"},{"key":"10.1016\/j.antiviral.2016.08.005_bib50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1473-3099(11)70033-0","article-title":"Why did maribavir fail in stem-cell transplants?","volume":"11","author":"Snydman","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.08.005_bib51","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1172\/JCI42955","article-title":"Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication","volume":"120","author":"Stanton","year":"2010","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.antiviral.2016.08.005_bib52","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.3390\/v7082834","article-title":"The interaction between cyclin B1 and cytomegalovirus protein kinase pUL97 is determined by an active kinase domain","volume":"7","author":"Steingruber","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2016.08.005_bib53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1099\/vir.0.83226-0","article-title":"Functional analysis of human cytomegalovirus pUS28 mutants in infected cells","volume":"89","author":"Stropes","year":"2008","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib54","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1128\/JVI.00192-14","article-title":"Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility","volume":"88","author":"Webel","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.08.005_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0166-3542(00)00118-2","article-title":"Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase","volume":"48","author":"Zimmermann","year":"2000","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216301930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216301930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T23:52:13Z","timestamp":1600991533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216301930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":56,"alternative-id":["S0166354216301930"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.08.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}